Cadila Healthcare Limited (Cadila) reported weak results for Q2FY2020. Revenue at Rs. 3,367 crore grew by 14% y-o-y but marginally missed our estimates. Operating profit at Rs. 626 crore fell by 9% y-o-y and was below our estimates. During the quarter, the company reported an exceptional loss of Rs. 268 crore on account of impairment towards Levorphanol. Adjusted PAT stood at Rs. 351 crore, down 15% y-o-y and was below our estimate of Rs. 365 crore. Following a warning letter from the US FDA, Cadila discontinued...